BRD1

Bromodomain-containing protein 1

12,093 patent compounds predicted against BRD1, 8,888 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2483189	0.45	11/20
SCHEMBL1450538	0.34	10/20
SCHEMBL1771879	0.47	9/20
SCHEMBL1948671	0.38	9/20
SCHEMBL2172818	0.47	8/20
SCHEMBL762351	0.44	8/20
Iguratimod (SCHEMBL26326)	0.36	8/20
SCHEMBL1535935	0.35	8/20
SCHEMBL422084	0.48	7/20
Flucarbril (SCHEMBL2109672)	0.43	7/20
SCHEMBL1356214	0.36	7/20
SCHEMBL1319712	0.49	6/20
SCHEMBL1238373	0.47	6/20
SCHEMBL1120017	0.44	6/20
SCHEMBL434941	0.49	5/20
SCHEMBL2474686	0.48	5/20
SCHEMBL1318489	0.50	4/20
SCHEMBL2118158	0.42	4/20
SCHEMBL2117319	0.42	4/20
SCHEMBL1630210	0.38	4/20

Germline variants in BRD1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BRD1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BRD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	PHASE3	COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC	PHASE2	NOT_YET_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma	PHASE1/PHASE2	RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial	PHASE2	RECRUITING
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	PHASE1	SUSPENDED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer	PHASE1	RECRUITING
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor	nan	NO_LONGER_AVAILABLE
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BRD1 binder may also engage these)

Protein	Name	Similarity
G5E8P1	—	1.000	G5E8P1 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.996	landscape →
Q5TKR9	—	0.994	Q5TKR9 →
BRPF1	Peregrin	0.994	landscape →
KDM4B	Lysine-specific demethylase 4B	0.993	landscape →
KAT8	Histone acetyltransferase KAT8	0.993	landscape →
B2KF05	—	0.993	B2KF05 →
Q7JVP4	—	0.993	Q7JVP4 →
Q32KD2	—	0.992	Q32KD2 →
A0JMQ9	—	0.992	A0JMQ9 →
Q28Z18	—	0.992	Q28Z18 →
KAT6B	Histone acetyltransferase KAT6B	0.991	landscape →
Q28D84	—	0.991	Q28D84 →
Q4V863	—	0.991	Q4V863 →
Q5SVQ0	—	0.991	Q5SVQ0 →
KDM5B	Lysine-specific demethylase 5B	0.991	landscape →
E1C2V1	—	0.991	E1C2V1 →
Q9UPV7	—	0.991	Q9UPV7 →
Q5XI06	—	0.991	Q5XI06 →
Q63553	—	0.991	Q63553 →
A0JMK9	—	0.991	A0JMK9 →
A3KMV1	—	0.990	A3KMV1 →
Q96P47	—	0.990	Q96P47 →
Q8BZ21	—	0.990	Q8BZ21 →
Q580W5	—	0.990	Q580W5 →
Q5EA28	—	0.990	Q5EA28 →
Q6P158	—	0.990	Q6P158 →
KAT7	Histone acetyltransferase KAT7	0.990	landscape →
O70445	—	0.990	O70445 →
Q6ZUT3	—	0.990	Q6ZUT3 →